

Article

Antiinflammatory activity of *Eugenia punicifolia* extract on muscular lesion of *mdx* dystrophic mice

Paulo Emílio Corrêa Leite ^{a,b,§}, Kessiane de Almeida Belshoff ^{a,d}, Jussara Lagrota-Candido ^b, Pablo Trindade ^c, Rafael Ferreira da Silva ^{a,b}, Manuel Gustavo L. Ribeiro ^a, Katia G. Lima-Araújo ^e, Wilson da Costa Santos ^d, Thereza Quirico-Santos ^{a,*}

^a Departamento de Biologia Celular e Molecular, ^b Departamento de Imunologia, ^c Departamento de Neurobiologia, ^d Departamento de Farmácia e Administração Terapêutica, ^e Departamento de Bromatologia; Universidade Federal Fluminense, Niterói, RJ, 24020-141, Brasil.

Conflicting interest statement: The authors declare no competing financial interests.

Received 17 August 2010; Revised 23 September 2010; Accepted 27 September 2010
Journal of Cellular Biochemistry
© 2010 Wiley-Liss, Inc.
DOI 10.1002/jcb.22906

Running Title: Antiinflammatory effects of *Eugenia punicifolia*

* Corresponding author: Thereza Quirico-Santos; Laboratory of Cellular Pathology, Institute of Biology, Federal Fluminense University, Niterói, RJ, 24020-141, Brazil; Tel.: +55 21 2629 2305; fax: +55 21 2629 2268. Email address: * tquirico@vm.uff.br (Thereza Quirico dos Santos); § leitepec@gmail.com.

Key words: **MUSCULAR DYSTROPHY; *mdx* MICE; *Eugenia punicifolia*; ACETYLCHOLINE RECEPTOR; SKELETAL MUSCLE.**

Number of figures: 5.

ABSTRACT

Eugenia punicifolia known as “pedra-ume caá” is a shrub largely distributed in the Amazon region popularly used in decoctions or infusions as a natural therapeutic agent, which can interfere on cholinergic nicotinic neurotransmission. This work aimed to investigate a putative antiinflammatory effect of dichloromethane fraction of *E. punicifolia* extract (*Ep*-CM) in the muscular lesion of *mdx* dystrophic mice, considering that activation of cholinergic mechanisms mitigates inflammation. A polymer containing the *Ep*-CM was implanted in *mdx* gastrocnemius muscle before onset of myonecrosis for local slow and gradual release of bioactive compounds and mice sacrificed 7 days or 9 weeks after surgery. Comparing to control muscle, treatment did not alter choline acetyltransferase and acetylcholinesterase enzymatic activities, but decreased metalloproteases -9 and -2 activities and levels of tumor necrosis factor α and NF κ B transcription factor. In addition, treatment also reduced levels of bioactive IL-1 β form and cleaved caspase-3, related to early events of cellular death and inflammatory activation and further increased myogenin expression without affecting collagen production which is associated with fibrosis. In vivo treatment of *mdx* dystrophic mice with *Ep*-CM caused significant reduction of muscular inflammation and improved skeletal muscle regeneration without inducing fibrosis.

INTRODUCTION

Natural products from plant extracts with potential pharmacological activity are extensively pursued for development of compounds or new lead structures with possible therapeutic applications in various pathologies [Rahimi et al., 2010]. One example is the Myrtaceae family constituted by more than 3,000 species and largely distributed in the Brazilian tropical Amazon region with the genus *Syzigium* and *Eugenia* commonly used for diarrhea and stomach disturbance, and as hypoglycemic medicament [Bopp et al., 2009; Brito et al., 2007]. The mechanism underlying pharmacological properties of the genus *Eugenia* may be partly related to flavonoids (myricitrin, quercetin, quercetrin), steroids, terpenoids, tanines and anthraquinones [Consolini and Sarubbio, 2002], but *E. puniceifolia* aqueous extract was able to enhance cholinergic nicotinic neurotransmission in the rat diaphragm muscle endplate model [Grangeiro et al., 2006].

Duchenne muscular dystrophy (DMD) is a human devastating X-linked recessive inflammatory myopathy in which progressive muscle degeneration is caused by a defect in the gene coding for dystrophin, a large cytoskeletal protein present in skeletal muscles and certain neurons [Voisin and de la Porte, 2004]. Lack of dystrophin leads to disruption of dystrophin-associated protein complex and sarcolemmal instability thus rendering activation of inflammatory signalling cascades. *Mdx* mouse, the animal model of human DMD presents similar pathological alterations with prominent muscle inflammation occurring soon after weaning (3 - 5 weeks) followed by cycles of degeneration and regeneration (8 - 12 weeks), and persistent fibrosis with accumulation of connective tissue at older age [Lagrota-Candido et al., 2002; Lefaucher and Sebille, 1996; McGeachie and Grounds, 1999]. Recent data from our group showed that activation of nicotinic acetylcholine receptor reduced inflammatory-mediated muscular lesion and improved muscle regeneration [Leite et al., 2010]. Based on relevant studies

about activation of the antiinflammatory cholinergic pathway [Tracey, 2009] and considering that increased expression of the non-neuronal nicotinic $\alpha 7$ acetylcholine receptor subunit (nAChR $\alpha 7$) plays an important role in the physiopathology of *mdx* muscular lesion [Leite et al., 2010], we reasoned that *E. punicifolia* extract could decrease inflammatory activation and improve tissue remodelling. To explore this hypothesis we employed *in vivo* experiments with a strategy to locally implant in the dystrophic gastrocnemius muscle a polymer containing *E. punicifolia* extract for slow and gradual release of compounds with putative biological activity.

MATERIALS AND METHODS

Plant material and preparation of the extract

Eugenia punicifolia was supplied by the Centro de Instrução de Guerra na Selva (CIGS, Manaus, AM, Brazil) and identified at the National Museum (Rio de Janeiro Federal University, Brazil). Official authorization for scientific investigation with plant components was given by the government environmental institution (IBAMA, Brazil), registered under the number 16602-1 with a voucher specimen deposited at the National Museum. The plant was successively extracted at room temperature with solvents of increasing polarity beginning with hexane, dichloromethane (CM) and methanol. The obtained extracts were evaporated to dryness and the residues stored at 4°C. Stock solutions (1 mg /mL) were prepared in 10⁻² M dimethyl sulfoxide (DMSO, Sigma Chem Co, USA).

Preparation of Elvax containing *Ep*-CM extract

Elvax, a polymer that allows slow and gradual release of substances was manufactured as described previously with minor modifications [Smith et al., 1995]. Briefly, ethylene-

vinyl acetate copolymer (Elvax 40W, DuPont, Pinheiros, SP, Brazil) was washed in 95% alcohol with multiple changes during 7 days. Elvax was dissolved in dichloromethane to give a 10% solution. 50 μ l of *Ep*-CM or methanolic fractions (2 mg/mL) were dissolved in DMSO or 50 μ l of vehicle DMSO with 1% Fast Green (to help visualizing Elvax slices) was added to the solution. Preparation was mixed up for 1 min and immediately placed in dry ice for 30 min, stored at -20°C for 5 days and further submitted to low vacuum pressure for 16 hs at 0°C followed by preparation of 200 μ m cryostat sections and stored at -20°C until implantation.

Animal care

Male *mdx* dystrophic and age-matched C57BL/10J control non-dystrophic mice were maintained at the Cellular Pathology animal house facilities at Fluminense Federal University. Mice were kept at constant temperature (20°C) with a light / dark cycle of 12 hours. Each cage housed up to 4 mice from the same age and offspring to minimize stress. Mice were sacrificed in the period of inflammatory prevalence at 4 weeks age and period of regeneration prevalence at 12 weeks age. All procedures were done within the guidelines established by the Brazilian College for Animal Experimentation (COBEA) and approved by the Institutional Animal Ethics Board.

At least five mice from each strain were separated on the following groups: Control, *mdx* mice without treatment; Vehicle, gastrocnemius muscle implanted with Elvax containing DMSO; CL, contralateral gastrocnemius muscle of *mdx* implanted with Elvax containing *Ep*-CM fraction; and Ep, gastrocnemius muscle of *mdx* mice implanted with Elvax containing *Ep*-CM fraction.

Elvax implantation

Male *mdx* mice with 3 week-old were anesthetized with 0.03 ml ketamine and 0.02 ml xylazine by intraperitoneal injection. A small skin incision was made with sterile steel blade, and Elvax containing 2 mg /mL of *Ep*-CM or vehicle DMSO was carefully placed on the left gastrocnemius muscle and incision closed with cyanoacrylate ester. Mice were killed 7 days or 9 weeks after surgery and both gastrocnemius muscles collected.

Choline acetyltransferase enzymatic activity analysis

Skeletal muscles were homogenized at 4°C with extraction solution (10 mM EDTA, 200 µM Eserin, 0.5% Triton X-100, 7 mM NaCl, 1 mM NaPO₄). Choline acetyltransferase (ChAT) activity was determined [Fonnum, 1975] with 0.1 µCi /tube of [³H] acetyl CoA (Amersham Biosciences, Fairfield, CT) as substrate. Briefly, the enzymatic activity at 37°C was measured in pH 7.4 with 10 µL of substrate solution (40 mM EDTA, 200 µM Eserin, 2 mM acetyl CoA, 40 mM choline, 1 M NaCl, 160 mM NaPO₄), 0.1 µCi [³H] acetyl CoA and 10 µL of the homogenized sample in extraction solution. As control, samples were incubated only with blank solution (10 mM EDTA, 0.5% Triton X-100 and 200 µM eserine). The enzymatic assay was performed for 15 min at 37°C, the reaction was stopped with 5 mL of 10 mM EDTA and 10 mL of Kalignost solution (5 mg /mL sodium tetraphenylborate in acetonitrile) under constant shaking for 30 sec. Tube content was transferred to other containing 10 mL of cintilation solution, and formation of two phases was observed. The Kalignost solution adsorbes all [³H] Acetyl CoA and [³H] ACh is released in the cintilation solution. Only [³H] ACh radioactivity counting for 1 min was analyzed (Packard, model 1600 TR) blank values were discounted. The values were divided by the specific activity of the radioactive substratum used, the time that the reaction lasted (15 min) and the amount of protein

present in each tube. As result, we obtained the specific activity of the enzyme in μ moles per minute per milligram of protein.

Acetylcholinesterase enzymatic activity analysis

Skeletal muscles were homogenized at 4°C in extraction buffer (0.05 M Tris-HCL pH 7.6) and acetylcholinesterase (AChE) activity determined [Ellman et al., 1961] using acetylthiocholine (ATCh) as substrate. Reaction medium consisted of 50 mM Tris-HCL pH 8.0, 100 mM MgCl₂, 10 mM ATCh, 10 mM DTNB (5:5-ditiobis-2-nitrobenzoic acid) and 10 μ L of homogenized sample in extraction buffer to a final volume of 1 mL. The method is based on the measurement of thiocholine production as ATCh is hydrolyzed at 25°C in the presence of DTNB producing a yellow anion detected at 412 nm (Hitachi, model U-3300). As result, we obtained the specific activity of the enzyme in μ moles per minute per milligram of protein.

Gelatin zymography

Gastrocnemius muscles from *mdx* and control mice were carefully removed, immediately frozen and preserved in liquid nitrogen (-196°C). Muscles were homogenized (1/10 w/v) in Tris-buffered saline (TBS, 100 mM Tris-HCl pH 7.6, 200 mM NaCl, 100 mM CaCl₂ and 1% Triton X-100). After centrifugation (12,000 x g, 10°C, 10 min), protein concentration in supernatant aliquots was determined [Lowry et al., 1951] and equal amounts of total protein loaded for zymography (60 μ g /lane). SDS-PAGE zymography was performed to determine gelatinase activity [Heussen and Dowdle, 1980]. Briefly, zymogram gels consisted of 7.5% polyacrylamide-SDS impregnated with 2 mg /ml type A gelatin from porcine skin (Sigma, St. Louis, MI) and 4% polyacrylamide-SDS for stacking gels. Gels were further washed twice for 30 min

in 2.5% Triton X-100 solution, then incubated at 37°C for 24 h in substrate buffer (10 mM Tris-HCl buffer, pH 7.5 with 5 mM CaCl₂, 1μM ZnCl₂). Gels were stained with 30% methanol /10% acetic acid solution containing 0.5% brilliant blue R-250 (Sigma, St Louis, MI) and discolored with the same solution without brilliant blue R-250. Gelatinase activity was visualized as unstained bands on a blue background representing areas of proteolysis.

Metalloproteases are secreted in a latent form and require cleavage of a NH₂ terminus peptide for activation. The exposure of proenzymes to SDS during gel separation leads to activation without proteolytic cleavage [Talhouk et al., 1992] with appearance of bands corresponding to 100-kDa (MMP-9), 66-kDa (pre-pro-MMP-2), 60-kDa (pro-MMP-2) and 55-kDa (active-MMP-2) [Kherif et al., 1999].

Western blotting

Skeletal muscles were homogenized with protease inhibitor buffer (Sigma, St Louis, MI). Protein extracts were clarified by centrifugation (12,000 x g for 15 min at 4°C), followed by quantification [Lowry et al., 1951] and concentration adjustment with sample buffer pH 6.8 (173 mM Tris, 30% glycerol, 3% sodium dodecyl sulfate, 3% β-mercaptoethanol, 0.1% bromophenol blue). Samples were denatured by boiling for 5 min and loaded on 12.5% SDS-PAGE for TNFα, IL-1β, cleaved-caspase-3 and HMGB1, and 10% for NFκB detection. Proteins were transferred to PVDF membranes (Hybond-P; Amersham Biosciences, Fairfield, CT) and blots carried out with Snap i.d (Millipore, USA) according to the manufacturer's recommendations. Membranes were blocked with 0.2% nonfat dry milk in 0.05% Tween-20 Tris-buffered saline (TBST) pH 7.4. Thereafter it was individually incubated with the primary rabbit polyclonal anti-NFκB p65 (A at 1:200) and anti-myogenin (at 1:350, Santa Cruz Biotechnology, CA),

anti-IL-1 β (at 1:5000; Peprotech, Rocky Hill, NJ) and anti-cleaved Caspase-3 (Asp175 at 1:350; Cell Signaling, Beverly, MA); goat anti-TNF α (L-19 at 1:200; Santa Cruz Biotechnology, Santa Cruz, CA) and monoclonal mouse anti-human HMGB1 (MAb1690 at 1:150 dilution; R&D Systems, Minneapolis, MN).

Peroxidase-conjugated rabbit anti-goat (Molecular Probes, Eugene, OR) was used for TNF α detection, goat anti-rabbit (Zymed, San Francisco, CA) for NF κ B p65 and cleaved Caspase-3 detection, and goat anti-mouse for HMGB1 detection (Zymed, San Francisco, CA) at 1:3000, 1:1500 and 1:2000, respectively. Bands were identified using ECL Plus (Amersham Biosciences, Fairfield, CT) for chemiluminescent detection and subsequent film exposure for 5 min. Presence of proteins were verified by comparing protein bands to the Molecular Rainbow Weight Marker (Amersham Biosciences; Fairfield, CT). As negative controls, samples were incubated without primary antibodies. Equal loading of protein was assessed on stripped blots by immunodetection of β -actin using peroxidase-conjugated goat anti-human polyclonal antibody diluted at 1:350 (at 1:1000, Santa Cruz Biotechnology, CA).

Apoptosis detection in situ

Gastrocnemius muscles from *mdx* mice were carefully removed, placed for 4 h in 4% paraformaldehyde solution and submitted to cryoprotection by sequential incubation with a gradient of sucrose solution (10%, 20% and 30% w/v in PBS) for 6 h at 4 °C in each solution. Cryostat cross-sections (10 μ m, spaced 200 μ m) were mounted on poly-L-lysine pre-coated slides and rinsed for 20 min in PBS. Terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling (TUNEL) method was utilized to identify the apoptotic cells (Upstate, Temecula, USA). In brief, after incubation of protein kinase for 30 min at 37°C and further washing steps, sections were labeled with biotinylated

nucleotides using Terminal deoxynucleotidyl Transferase (TdT) enzyme for 1 h in a humidity chamber at 37°C. The incorporated nucleotides were detected using avidin-FITC-labeled solution in the dark for 30 min at 37°C and sections were counterstained with Dapi. Images were randomly obtained with a Nikon Eclipse TE2000-U microscope with identical time exposure and image settings and merged on Adobe Photoshop CS3.

Histological staining and morphometric analysis

Gastrocnemius muscles from *mdx* mice were carefully removed and fixed in formalin-buffered Millonig fixative (pH 7.2) for 24 hs. 5 µm-thick sections of wax-embedded material were stained with hematoxylin-eosin and sirius red for collagen. High definition whole area images of all cross-sections from each *mdx* mouse at a time point were obtained from individual photomicrographs with a microdigital camera mounted on a Zeiss Axioplan microscope (Zeiss, Oberkochen, Germany) using a 20x objective. Images were blended using Adobe Photoshop CS3 Extended software. Total surface area and areas occupied by inflammatory infiltrates and collagen deposition were determined with Image-Pro 4.5 (Media Cybernetics, Inc.). Results were expressed as percentage of total area in the cross-section.

Quantitative and Statistical Analysis

All experiments were conducted in at least triplicates. Quantitative analysis was performed using the image-analysis software Scion Image for Windows (Scion Corporation, National Institutes of Health; Bethesda, MD) for ChAT and AChE enzymatic activity analysis, zymography, western blotting, TUNEL and morphometry. GraphPad Prism 5 (GraphPad software Inc.) was used to calculate mean and standard deviations. One-way ANOVA and unpaired *t* test were applied to obtain statistical

significance of means. Differences were considered to be statistically significant at the 0.05 level of confidence.

RESULTS

Effect of E. puniceifolia treatment on ChAT and AChE activities in mdx skeletal muscle

E. puniceifolia aqueous extract exerts pro-cholinergic effects [Grangeiro et al., 2006] but *in vivo* treatment with methanolic or the dichloromethanic fraction of *E. puniceifolia* did not modify ChAT and AChE enzymatic activities in the gastrocnemius muscle of *mdx* mice (Fig 1A, B).

E. puniceifolia treatment decreases MMPs -9 and -2 activities in mdx skeletal muscle

Activities of MMP -9 and -2 in *mdx* gastrocnemius muscle were analyzed as indicators of local inflammation and tissue remodelling, respectively. Muscle of *mdx* mice treated with *Ep*-CM from 3 to 4 weeks of age during the period of prominent muscular inflammation showed significant reduction of MMP-9 ($62 \pm 12\%$, $p < 0.005$) and MMP-2 ($58 \pm 10\%$, $p < 0.005$) activities in comparison with *mdx* muscle implanted with vehicle (Fig 2). It was not observed any effect with the methanolic fraction.

E. puniceifolia treatment decreases production of inflammatory proteins in mdx skeletal muscle

Ep-CM implant during 7 days reduced TNF α production ($42 \pm 9\%$, $p < 0.01$; Fig 3A) and NFkB expression ($48 \pm 7\%$, $p < 0.005$; Fig 3B) in *mdx* gastrocnemius muscle in comparison with control groups.

Interleukin 1 β (IL-1 β) was detected in four forms: 35 and 28-kDa pro-IL-1 β , a cleaved 22-kDa inactive and a cleaved 17.5-kDa bioactive form [Yao et al., 2006]. It was

observed reduced expression levels only of the 17.5-kDa IL-1 β bioactive form after *Ep*-CM treatment in comparison with *mdx* muscle implanted with vehicle implant ($54 \pm 13\%$, $p < 0.05$, Fig 3C). It was not observed significant alteration of the pro-inflammatory protein high mobility group box 1 (HMGB1) (Fig 3D).

E. puniceifolia treatment reduces apoptosis in *mdx* skeletal muscle

TUNEL was used to assess myofibers undergoing apoptosis. Treatment of *mdx* gastrocnemius muscle at 4 weeks during active myonecrosis with *Ep*-CM caused a reduction of $38\% \pm 13\%$ ($p < 0.05$) in the number of myofibers with fragmented DNA compared with vehicle implant (Fig 4A, B). Likewise, reduced expression of cleaved caspase-3 ($40 \pm 9\%$, $p < 0.05$) which corresponds to apoptosis signaling cascade activation was consistently observed in muscle homogenates from *Ep*-CM implant in comparison with vehicle implant (Fig 4C).

E. puniceifolia treatment during 9 weeks reduces inflammatory infiltrate and improves regeneration of *mdx* skeletal muscle

In order to assess if prolonged treatment with the *Ep*-CM extract would influence *mdx* inflammatory lesion, it was analyzed whole cross-sections of *mdx* gastrocnemius muscles from 5 different mice. The total area of inflammatory infiltrate in gastrocnemius muscle from vehicle implanted and the contralateral muscle corresponded to $8 \pm 1\%$ of the total muscle. In contrast, it was observed a marked reduction of the inflammatory lesion area ($86 \pm 22\%$; $p < 0.05$; Fig 5A) in *Ep*-CM polymer implant in *mdx* gastrocnemius muscle.

Myogenin content was used as a parameter of protein marker of late muscular regeneration. *Mdx* control mice at 12 weeks showed muscle regeneration associated

with marked deposition of connective tissue. Skeletal muscles from *mdx* mice implanted with *Ep*-CM showed a significant increase of myogenin content in relation to the contralateral muscle and muscle with vehicle implant ($44 \pm 12\%$, $p < 0.05$; Figure 5B), but no significant alteration in the collagen content (Fig 5C).

DISCUSSION

Several studies have shown that activation of cholinergic mechanisms mitigate inflammation in several mouse models of diseases [Osborne-Hereford et al., 2008; Rosas-Ballina et al., 2008; van Maanen et al., 2009; van Westerloo et al., 2005]. Previous data showed that *E. punicifolia* aqueous extract used as a natural pharmacological agent with putative action upon cholinergic neurotransmission [Grangeiro et al., 2006] was able to totally recover the effects of the cholinergic nicotinic competitive antagonists pancuronium and gallamine in the neuromuscular junction of rat diaphragm. It was also proposed that the aqueous extract had acetylcholinesterase inhibitory activity. Since then, investigation in other experimental models and the utilization of chemical fractions of the plant extract were carried out in attempt to recognize class of compounds capable to inhibit the cholinergic neurotransmission. Recently we showed that nAChR activation influences local inflammatory responses in the muscular lesion of *mdx* mice [Leite et al., 2010]. We fractionated the *E. punicifolia* extract with solvents of different polarities: hexane, dichloromethane and methanol, but results with statistical relevance were obtained only with the dichloromethane fraction. We present evidence that local *in vivo* treatment with the dichloromethane fraction exerts antiinflammatory properties in the gastrocnemius muscle of *mdx* dystrophic mice by mechanisms not related to the cholinergic activation.

In the present work we demonstrate that the *Ep*-CM fraction was not able to induce the synthesis of acetylcholine *in vivo*, since *in situ* ChAT and AChE activities were not altered after treatment with the *Ep*-CM. Such results ruled out the possibility that *Ep*-CM would inhibit the action of AChE and amplify acetylcholine-receptor interaction. It remains to be elucidated the mechanism by which aqueous *E. puniceifolia* extract presents pro-cholinergic properties via activating receptors and /or by the competition for the receptor site with specific antagonists.

TNF α , considered a major indicator of local inflammation amplifies and prolongs the inflammatory response by activating other cells to increase TNF α production, NF κ B activation, IL-1 β , HMGB1 [Tracey, 2002] and MMP-9 [Kherif et al., 1999]. The protein exists as a 27-kDa membrane-bound precursor that can be processed by TNF α converting enzyme (TACE) and MMP-9 to generate a 17-kDa mature TNF α [Kherif et al., 1999; Mullberg et al., 2000]. TNF α up-regulation activates the signalling cascade downstream of the NF κ B activation, including activation of I kappa B kinase (IKK) followed by I κ B proteins phosphorylation, NF κ B translocation, and subsequent gene transcription resulting in increased TNF α protein production [Yoshikawa et al., 2006]. Increased levels of these inflammatory proteins can result in cellular apoptosis [Tracey, 2007] and induce the activation of NF κ B, which is a class of protein that responds to stimuli by activating the expression of numerous genes, including those involved with cellular proliferation, migration, angiogenesis and inflammation. NF κ B activation can thus amplify production of several inflammatory proteins.

The present results demonstrate that local treatment with *Ep*-CM reduced MMPs activity, production of the 17-kDa TNF α and 17.5-kDa IL-1 β bioactive forms, and NF κ B. In addition, treatment reduced apoptosis, determined by cleaved caspase-3 immunodetection and myofibers with fragmenting of DNA during active myonecrosis

stage of *mdx* gastrocnemius muscles. Yet, HMGB1 levels were not altered by treatment.

This protein is highly related to induction of inflammation and severe sepsis only when secreted, but has an important physiologic role in the structural dynamics by facilitating gene transcription and DNA repair [Lange and Vasquez, 2009]. This suggests that HMGB1 levels correspond to its normal nuclear content, since wild type non-dystrophic mice showed similar levels (data not shown). It is conceivable that *Ep*-CM treatment downregulated activation of genes associated with inflammatory proteins.

Ep-CM treatment during seven days did not increase myogenin expression which is associated with myofiber regeneration (data not shown) but decreased production of inflammatory mediators and further contributed to efficient skeletal muscle repair in *mdx* dystrophic mice evidenced by increased myogenin levels after 9 weeks of treatment. Indeed controlled production of inflammatory mediators are associated with reduction of muscle wasting [Rendon-Mitchell et al., 2003] and NF κ B activation [Messina et al., 2006] which can upregulate myogenic transcription factor MyoD, essential for new muscle fiber formation [Guttridge et al., 2000]. In this sense, the local treatment with *E. puniceifolia* extract decreased the mentioned inflammatory mediators, and seems to have contributed to efficient skeletal muscle repair in *mdx* dystrophic mice evidenced by increased myogenin levels, without affecting collagen deposition and induce the non-functional fibrosis by a yet unknown mechanism.

The present work shows that local treatment with *Ep*-CM decreased production of inflammatory mediators, reduced apoptosis and contributed to efficient muscular regeneration of *mdx* dystrophic mice, without inducing fibrosis. Future studies are necessary to isolate all bioactive substance(s) from *Eugenia puniceifolia* and determine their effects in mitigating myopathy and /or promoting activation of mechanisms related

with efficient muscular regeneration, and evaluating its potential use in the treatment of DMD and other inflammatory diseases.

ACKNOWLEDGEMENTS

This study was supported by grants from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), CNPq (Conselho Nacional de Pesquisa e Desenvolvimento Tecnológico) and FAPERJ (Fundação de Amparo a Pesquisa do Rio de Janeiro).

Authors are indebted to Centro de Instrução de Guerra na Selva (CIGS), Manaus, AM, Brasil for the provision of plants. We thank Dr. Ricardo N. Isayama from Institute of Biophysics Carlos Chagas Filho – UFRJ for providing the TUNEL kit reagent.

REFERENCES

- Bopp A, De Bona KS, Belle LP, Moresco RN, Moretto MB. 2009. *Syzygium cumini* inhibits adenosine deaminase activity and reduces glucose levels in hyperglycemic patients. *Fundam Clin Pharmacol* 23:501-7.
- Brito FA, Lima LA, Ramos MF, Nakamura MJ, Cavalher-Machado SC, Siani AC, Henriques MG, Sampaio AL. 2007. Pharmacological study of anti-allergic activity of *Syzygium cumini* (L.) Skeels. *Braz J Med Biol Res* 40:105-15.
- Consolini AE, Sarubbio MG. 2002. Pharmacological effects of *Eugenia uniflora* (Myrtaceae) aqueous crude extract on rat's heart. *J Ethnopharmacol* 81:57-63.
- Ellman GL, Courtney KD, Andres V, Jr., Feather-Stone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 7:88-95.
- Fonnum F. 1975. A rapid radiochemical method for the determination of choline acetyltransferase. *J Neurochem* 24:407-9.
- Grangeiro MS, Calheiros-Lima AP, Martins MF, Arruda LF, Garcez-do-Carmo L, Santos WC. 2006. Pharmacological effects of *Eugenia punicifolia* (Myrtaceae) in cholinergic nicotinic neurotransmission. *J Ethnopharmacol* 108:26-30.
- Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS, Jr. 2000. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. *Science* 289:2363-6.
- Heussen C, Dowdle EB. 1980. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. *Anal Biochem* 102:196-202.
- Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, Verdiere-Sahuque M, Fardeau M, Alameddine HS. 1999. Expression of matrix metalloproteinases 2 and 9 in

regenerating skeletal muscle: a study in experimentally injured and mdx muscles. *Dev Biol* 205:158-70.

Lagrota-Candido J, Vasconcellos R, Cavalcanti M, Bozza M, Savino WQ, Quirico-Santos T. 2002. Resolution of skeletal muscle inflammation in mdx dystrophic mouse is accompanied by increased immunoglobulin and interferon-g production. *Intern. J. Exp. Pathol.* 83:121-132.

Lange SS, Vasquez KM. 2009. HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. *Mol Carcinog* 48:571-80.

Lefaucher JP, Sebillé A. 1996. Features of dystrophy in smooth and skeletal muscles of mdx mice. *Muscle & Nerve*:793-794.

Leite PE, Lagrota-Candido J, Moraes L, D'Elia L, Pinheiro DF, da Silva RF, Yamasaki EN, Quirico-Santos T. 2010. Nicotinic acetylcholine receptor activation reduces skeletal muscle inflammation of mdx mice. *J Neuroimmunol.*

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. *J Biol Chem* 193:265-75.

McGeachie JK, Grounds MD. 1999. The timing between skeletal muscle myoblast replication and fusion into myotubes, and the stability of regenerated dystrophic myofibres: an autoradiographic study in mdx mice. *J. Anat.* 194:287-295.

Messina S, Bitto A, Aguenouz M, Minutoli L, Monici MC, Altavilla D, Squadrito F, Vita G. 2006. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. *Exp Neurol* 198:234-41.

Mullberg J, Althoff K, Jostock T, Rose-John S. 2000. The importance of shedding of membrane proteins for cytokine biology. *Eur Cytokine Netw* 11:27-38.

Osborne-Hereford AV, Rogers SW, Gahring LC. 2008. Neuronal nicotinic alpha7 receptors modulate inflammatory cytokine production in the skin following ultraviolet radiation. *J Neuroimmunol* 193:130-9.

Rahimi R, Ghiasi S, Azimi H, Fakhari S, Abdollahi M. 2010. A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. *Cytokine* 49:123-9.

Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, Sama AE, Tracey KJ. 2003. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. *J Immunol* 170:3890-7.

Rosas-Ballina M, Ochani M, Parrish WR, Ochani K, Harris YT, Huston JM, Chavan S, Tracey KJ. 2008. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. *Proc Natl Acad Sci U S A* 105:11008-13.

Smith AL, Cordery PM, Thompson ID. 1995. Manufacture and release characteristics of Elvax polymers containing glutamate receptor antagonists. *J Neurosci Methods* 60:211-7.

Talhouk RS, Bissell MJ, Werb Z. 1992. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. *J Cell Biol* 118:1271-82.

Tracey KJ. 2002. The inflammatory reflex. *Nature* 420:853-9.

Tracey KJ. 2007. Physiology and immunology of the cholinergic antiinflammatory pathway. *J Clin Invest* 117:289-96.

Tracey KJ. 2009. Reflex control of immunity. *Nat Rev Immunol* 9:418-28.

van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP. 2009. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. *Arthritis Rheum* 60:114-22.

van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, van der Poll T. 2005. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. *J Infect Dis* 191:2138-48.

Voisin V, de la Porte S. 2004. Therapeutic strategies for Duchenne and Becker dystrophies. *Int Rev Cytol* 240:1-30.

Yao C, Karabasil MR, Purwanti N, Li X, Akamatsu T, Kanamori N, Hosoi K. 2006. Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice. *J Biol Chem* 281:7968-76.

Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N. 2006. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. *Clin Exp Immunol* 146:116-23.




Fig 1.





Fig 2.




Fig 3.





Fig 4.




Fig 5.